GlassScriptPhysician profile
Aron Kumar T Reddy
NPI 1255533592
$2,470.35
in general payments reported to CMS, 2019-2025
22 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.53 · 2020: $134 · 2021: $401 · 2022: $105 · 2023: $321 · 2024: $795 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.24 | 2021-2025 | |
| Pfizer INC. | $221.60 | 2023-2025 | |
| Axsome Therapeutics, INC. | $159.60 | 2025 | Symbravo |
| Ars Pharmaceuticals Operations, INC. | $124.06 | 2025 | Neffy |
| Acadia Pharmaceuticals INC | $121.85 | 2021-2024 | Nuplazid |
| Allergan, INC. | $83.72 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $68.04 | 2024-2025 | Ajovy |
| Novartis Pharmaceuticals Corporation | $66.66 | 2020-2025 | |
| Ge Healthcare | $57.14 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $56.05 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $48.43 | 2025 | Crexont |
| Amgen INC. | $45.97 | 2020-2024 | Aimovig |
| Supernus Pharmaceuticals, INC. | $42.18 | 2021 | |
| Sumitomo Pharma America, INC. | $37.67 | 2023 | Aptiom |
| Eisai INC. | $25.77 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $22.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.92 | 2020 | |
| Biogen, INC. | $18.87 | 2021 | |
| Neurocrine Biosciences, INC. | $16.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
| Zogenix INC. | $12.60 | 2021 | |
| Lilly USA, LLC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aron Kumar Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.